Soligenix Revenue 2010-2022 | SNGX

Soligenix revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Soligenix Annual Revenue
(Millions of US $)
2021 $1
2020 $2
2019 $5
2018 $5
2017 $5
2016 $10
2015 $9
2014 $7
2013 $3
2012 $3
2011 $8
2010 $2
2009 $3
Soligenix Quarterly Revenue
(Millions of US $)
2022-03-31 $0
2021-12-31 $0
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
2020-12-31 $0
2020-09-30 $1
2020-06-30 $1
2020-03-31 $1
2019-12-31 $1
2019-09-30 $1
2019-06-30 $2
2019-03-31 $1
2018-12-31 $1
2018-09-30 $1
2018-06-30 $2
2018-03-31 $1
2017-12-31 $1
2017-09-30 $2
2017-06-30 $1
2017-03-31 $1
2016-12-31 $2
2016-09-30 $3
2016-06-30 $3
2016-03-31 $3
2015-12-31 $3
2015-09-30 $4
2015-06-30 $1
2015-03-31 $1
2014-12-31 $2
2014-09-30 $3
2014-06-30 $1
2014-03-31 $1
2013-12-31 $1
2013-09-30 $0
2013-06-30 $1
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31 $1
2011-12-31 $1
2011-09-30 $6
2011-06-30 $0
2011-03-31 $1
2010-12-31 $0
2010-09-30 $1
2010-06-30 $0
2010-03-31 $0
2009-12-31 $1
2009-09-30 $1
2009-06-30 $0
2009-03-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.026B $0.001B
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00